Arkolith/Insider Trading/PRLD/Form 4

Vaddi Krishna

CEO, DirectorPrelude Therapeutics Inc (PRLD) · full profile →Form 4 · filed Dec 20, 2024
Net Buying
Open-Market Buys
$99K
Open-Market Sells
$0
Net Open-Market Flow
$99K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 19, 2024Buy(P)7K$0.89$6K128K
Dec 18, 2024Buy(P)100K$0.93$93K1.2M

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-24-008531) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML